



5 August 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

McPherson's CEO joins Medlab Clinical Board

Medlab Clinical (ASX.MDC) a company with a portfolio of novel drug candidates, including cannabinoids and nutraceuticals, enhanced by its drug delivery platform and used for the treatment of chronic pain and disease, is pleased to announce that it has appointed Mr Laurence McAllister as an Independent Non-Executive Director of the company, effective today, 5 August.

Mr McAllister is currently CEO of McPherson's Limited (ASX.MCP) a global consumer goods company in the Health, Wellness & Beauty sector with a market capitalisation of ~\$316M. Under his leadership McPherson's has delivered an impressive turnaround, growing annual sales revenue to \$220M. He brings strong experience in consumer marketing and extensive commercial, M&A and business strategy experience.

Mr McAllister was previously Managing Director for Sanofi in Australia & New Zealand, where he successfully led and turned around the company's consumer healthcare business. During his tenure at Sanofi he also served on the Board of Medicines Australia for two years.

He has also spent more than 23 years in a variety of management positions for one of the largest and most recognised retail brands, Coca Cola, operating across Australia, Asia, Europe and the Middle East. In addition, Mr McAllister was previously President at Trax Retail, an innovative retail digital imaging recognition solution provider offering in-store execution tools, market measurement services and data science solutions.

Mr McAllister commented: "I am delighted to join the Board of Medlab Clinical. I was drawn to the quality and the breadth of its portfolio of nutraceutical products and novel drug candidates, and see a great opportunity for it to become a highly differentiated and successful player in prescription and over-the-counter healthcare. I look forward to leveraging my experience in consumer health/ FMCG, global pharmaceutical industry and leading an ASX listed company to help guide the business through its next stage of growth."

"This is the first new Board appointment since our IPO in 2015 and we are pleased to welcome a leader of his calibre. Laurie's global experience, across marketing and strategy, and success in building recognisable healthcare brands will be invaluable as we continue to advance development and commercial rollout of our portfolio of novel drug candidates," said Mr Michael Hall, Chairman of Medlab Clinical.

“In recognition of his experience and the value Mr McAllister brings to the Company, the Board has agreed to issue 4m unlisted options at 18c with an expiry date of two years. These options are subject to shareholder approval at the 2020 Annual General Meeting of Shareholders,” Mr Michael Hall further commented.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™ is being applied to its medicines, nutritional products and off-patent drugs like statins, Medlab has a growing patent portfolio.

For further information contact:

Dr Sean Hall, CEO Medlab Clinical T: + 61 2 8203 9520 – sean_hall@medlab.co	Kyahn Williamson, WE Communications T: + 61 0401018828 - kwilliamson@we-worldwide.com
---	--